Conference Details - Overview
Fifth Annual New York Lung Cancer Symposium
The Westin New York at Times Square
New York, NY
November 10, 2009
Conference Overview
CME-Certified Symposium
This activity is presented by Physicians’ Education Resource in conjunction with the Albert Einstein College of Medicine & Montefiore Medical Center.
The Fifth Annual New York Lung Cancer Symposium will bring key data on lung cancer from international oncology conferences to attending physicians. The newfound importance of pathology in treatment decision making will be emphasized, followed by other current topics of interest, such as maintenance therapy. The optimization of targeted agents, including EGFR and angiogenesis inhibitors, will be discussed, as will novel targets including EML4-ALK and the IGF-1R pathway. New approaches to early-stage lung cancer and chemoprevention will be presented, and interventions for adverse events associated with newer agents will be discussed. Didactic lectures and debates from lung cancer experts will set the stage for discussion sessions and opportunities for participants to interact with faculty. The symposium will also feature a case discussion session that will allow fellows to actively participate in the program.
This educational program is directed toward medical oncologists, radiation oncologists, and thoracic surgeons specializing in lung cancer. Fellows, nurses, and pharmacists in oncology who are interested in the treatment of lung cancer are also invited to attend.At the conclusion of this symposium, you should be able to:
- Assess the role of maintenance therapy with cytotoxic and targeted agents in lung cancer
- Discuss approaches to obtain pathologic characteristics from small lung cancer biopsy specimens
- Identify molecular subtypes of lung cancer based on gene mutations, microRNA levels, and protein expression
- Assess the feasibility and efficacy of nonsurgical approaches to early lung cancer
- Describe current data on angiogenesis inhibitors in lung cancer
- Summarize the biology of and therapeutic approaches to EML4-ALK–positive NSCLC
- Review clinical data on IGF-1R inhibitors
- Analyze approaches to optimize the use of EGFR inhibitors in lung cancer
- Describe interventions to ameliorate the adverse events associated with targeted agents in lung cancer therapy
- Discuss chemopreventive approaches to lung cancer